Soleno Therapeutics is a biopharmaceutical company that develops innovative treatments for rare diseases. The company's lead candidate is Diazoxide Choline Controlled-Release, an oral tablet that treats Prader-Willi Syndrome in a once-daily dose. Founded in 1999 as Capnia, the company changed its name to Soleno Therapeutics in 2017 and has its headquarters in California.